EQUIVALENT OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA PATIENTS WHO HAD T (8;21) WITH AND WITHOUT ADDITIONAL ABERATIONS
(Abstract release date: 05/19/16)
EHA Library. Chen H. 06/09/16; 133086; E1537
Dr. Huan Chen
Contributions
Contributions
Abstract
Abstract: E1537
Type: Eposter Presentation
Background
Although acute myeloid leukemia (AML) patients who had t(8;21) had favorable outcome after high-dose therapy with autologous stem cell transplantation(ASCT). It was still a heterogeneous disease. Limited data was reported about outcome in AML patients who had t(8;21) with additional cytogenetic abnormalities after ASCT.
Aims
In the current cohort study we investigated long-term survival of AML patients who had t(8;21) with and without additional aberations after ASCT.
Methods
Patients with de novel AML who had t(8;21) with or without additional cytogenetic abnormalities, younger than 60 years were eligible. G banding and FISH analysis were performed to test cytogenetic aberations. Peripheral blood stem cell (PBSC) harvesting was started if patients achieved CR1 and MRD level was less than 0.1% after 1 to 2 courses of induction therapy(3+7) and at least 2-coursrs of consolidation therapy including high-dose Ara-C. MRD was monitored using real-time PCR (RT-PCR) to quantify the RUNX1/RUNX1T, The conditioning regimen was busulphan/cytoxan.
Results
between March 2008 and March 2014, 27 eligible patients were enrolled. All enrolled patients were Chinese. Median age was 30 years (range, 13- 56 years). Fourteen patients were male and 13 were female. Eleven patients had additional aberrations, including –y (n=6), -x (n=2), del (8q) (n=1), del(9q) (n=1), del(9q) and –x (n=1). Patients’ characteristics between the two groups were comparable. At the median follow-up 46 months (range,6.5 to 92 months) after consolidation therapy, the 5-year leukemia-free survival (LFS) and overall survival (OS) for the total patients were 88.9% ± 6.0% and 90.3% ±6.8% after consolidation therapy. For the patients with and without additional aberations, LFS were 87.5% and. 90.9%, p=0.832. OS were 90.8% and 90.9%, p=0.752, respectively. Two relapse patients after ASCT received haploidentical related transplantation and were still alive in CR after following-up 74 and 64 months.
Conclusion
AML patients who had t (8;21) with and without additional aberations had equivalent long-term survival after ASCT in Chinese, if patient achieved CR1 with MRD level less than 0.1% before transplant. Allogeneic HSCT including haploidentical related transplant is a salvage therapy for relapse patients after ASCT.
Session topic: E-poster
Type: Eposter Presentation
Background
Although acute myeloid leukemia (AML) patients who had t(8;21) had favorable outcome after high-dose therapy with autologous stem cell transplantation(ASCT). It was still a heterogeneous disease. Limited data was reported about outcome in AML patients who had t(8;21) with additional cytogenetic abnormalities after ASCT.
Aims
In the current cohort study we investigated long-term survival of AML patients who had t(8;21) with and without additional aberations after ASCT.
Methods
Patients with de novel AML who had t(8;21) with or without additional cytogenetic abnormalities, younger than 60 years were eligible. G banding and FISH analysis were performed to test cytogenetic aberations. Peripheral blood stem cell (PBSC) harvesting was started if patients achieved CR1 and MRD level was less than 0.1% after 1 to 2 courses of induction therapy(3+7) and at least 2-coursrs of consolidation therapy including high-dose Ara-C. MRD was monitored using real-time PCR (RT-PCR) to quantify the RUNX1/RUNX1T, The conditioning regimen was busulphan/cytoxan.
Results
between March 2008 and March 2014, 27 eligible patients were enrolled. All enrolled patients were Chinese. Median age was 30 years (range, 13- 56 years). Fourteen patients were male and 13 were female. Eleven patients had additional aberrations, including –y (n=6), -x (n=2), del (8q) (n=1), del(9q) (n=1), del(9q) and –x (n=1). Patients’ characteristics between the two groups were comparable. At the median follow-up 46 months (range,6.5 to 92 months) after consolidation therapy, the 5-year leukemia-free survival (LFS) and overall survival (OS) for the total patients were 88.9% ± 6.0% and 90.3% ±6.8% after consolidation therapy. For the patients with and without additional aberations, LFS were 87.5% and. 90.9%, p=0.832. OS were 90.8% and 90.9%, p=0.752, respectively. Two relapse patients after ASCT received haploidentical related transplantation and were still alive in CR after following-up 74 and 64 months.
Conclusion
AML patients who had t (8;21) with and without additional aberations had equivalent long-term survival after ASCT in Chinese, if patient achieved CR1 with MRD level less than 0.1% before transplant. Allogeneic HSCT including haploidentical related transplant is a salvage therapy for relapse patients after ASCT.
Session topic: E-poster
Abstract: E1537
Type: Eposter Presentation
Background
Although acute myeloid leukemia (AML) patients who had t(8;21) had favorable outcome after high-dose therapy with autologous stem cell transplantation(ASCT). It was still a heterogeneous disease. Limited data was reported about outcome in AML patients who had t(8;21) with additional cytogenetic abnormalities after ASCT.
Aims
In the current cohort study we investigated long-term survival of AML patients who had t(8;21) with and without additional aberations after ASCT.
Methods
Patients with de novel AML who had t(8;21) with or without additional cytogenetic abnormalities, younger than 60 years were eligible. G banding and FISH analysis were performed to test cytogenetic aberations. Peripheral blood stem cell (PBSC) harvesting was started if patients achieved CR1 and MRD level was less than 0.1% after 1 to 2 courses of induction therapy(3+7) and at least 2-coursrs of consolidation therapy including high-dose Ara-C. MRD was monitored using real-time PCR (RT-PCR) to quantify the RUNX1/RUNX1T, The conditioning regimen was busulphan/cytoxan.
Results
between March 2008 and March 2014, 27 eligible patients were enrolled. All enrolled patients were Chinese. Median age was 30 years (range, 13- 56 years). Fourteen patients were male and 13 were female. Eleven patients had additional aberrations, including –y (n=6), -x (n=2), del (8q) (n=1), del(9q) (n=1), del(9q) and –x (n=1). Patients’ characteristics between the two groups were comparable. At the median follow-up 46 months (range,6.5 to 92 months) after consolidation therapy, the 5-year leukemia-free survival (LFS) and overall survival (OS) for the total patients were 88.9% ± 6.0% and 90.3% ±6.8% after consolidation therapy. For the patients with and without additional aberations, LFS were 87.5% and. 90.9%, p=0.832. OS were 90.8% and 90.9%, p=0.752, respectively. Two relapse patients after ASCT received haploidentical related transplantation and were still alive in CR after following-up 74 and 64 months.
Conclusion
AML patients who had t (8;21) with and without additional aberations had equivalent long-term survival after ASCT in Chinese, if patient achieved CR1 with MRD level less than 0.1% before transplant. Allogeneic HSCT including haploidentical related transplant is a salvage therapy for relapse patients after ASCT.
Session topic: E-poster
Type: Eposter Presentation
Background
Although acute myeloid leukemia (AML) patients who had t(8;21) had favorable outcome after high-dose therapy with autologous stem cell transplantation(ASCT). It was still a heterogeneous disease. Limited data was reported about outcome in AML patients who had t(8;21) with additional cytogenetic abnormalities after ASCT.
Aims
In the current cohort study we investigated long-term survival of AML patients who had t(8;21) with and without additional aberations after ASCT.
Methods
Patients with de novel AML who had t(8;21) with or without additional cytogenetic abnormalities, younger than 60 years were eligible. G banding and FISH analysis were performed to test cytogenetic aberations. Peripheral blood stem cell (PBSC) harvesting was started if patients achieved CR1 and MRD level was less than 0.1% after 1 to 2 courses of induction therapy(3+7) and at least 2-coursrs of consolidation therapy including high-dose Ara-C. MRD was monitored using real-time PCR (RT-PCR) to quantify the RUNX1/RUNX1T, The conditioning regimen was busulphan/cytoxan.
Results
between March 2008 and March 2014, 27 eligible patients were enrolled. All enrolled patients were Chinese. Median age was 30 years (range, 13- 56 years). Fourteen patients were male and 13 were female. Eleven patients had additional aberrations, including –y (n=6), -x (n=2), del (8q) (n=1), del(9q) (n=1), del(9q) and –x (n=1). Patients’ characteristics between the two groups were comparable. At the median follow-up 46 months (range,6.5 to 92 months) after consolidation therapy, the 5-year leukemia-free survival (LFS) and overall survival (OS) for the total patients were 88.9% ± 6.0% and 90.3% ±6.8% after consolidation therapy. For the patients with and without additional aberations, LFS were 87.5% and. 90.9%, p=0.832. OS were 90.8% and 90.9%, p=0.752, respectively. Two relapse patients after ASCT received haploidentical related transplantation and were still alive in CR after following-up 74 and 64 months.
Conclusion
AML patients who had t (8;21) with and without additional aberations had equivalent long-term survival after ASCT in Chinese, if patient achieved CR1 with MRD level less than 0.1% before transplant. Allogeneic HSCT including haploidentical related transplant is a salvage therapy for relapse patients after ASCT.
Session topic: E-poster
{{ help_message }}
{{filter}}